The molecular characteristics are shown in Table 1 (and the Data Supplement for all FOCUS4 participants), showing that only 37% had an RAS wild-type tumor reflecting NHS England policy of not allowing treatment breaks for patients on epidermal growth factor receptor monoclonal antibodies. The gene discussed is EGFR; the disease is neoplasm.